Abstract：
New insights have been gained on the role of platelets beyond thrombosis. Platelets can accumulate in damaged and inflamed tissues, acting as a sentinel to detect and repair tissue damage. However, by releasing several soluble factors, including thromboxane A2 (TXA2) and 12-hydroxyeicosatetraenoic acid, and extracellular vesicles (EVs), platelets can activate vascular cells, stromal, such as fibroblasts, immune cells, and cancer cells, leading to atherosclerosis, vascular restenosis, tissue fibrosis, and tumor metastasis. Platelet-derived extracellular vesicles (PEVs) are released when platelets are activated and can transfer their cargo to other cell types, thus contributing to the development of diseases. Inhibitors of the internalization of PEVs can potentially represent novel therapeutic tools. Both platelets and PEVs contain a significant number of different types of molecules, and their omics assessment and integration with clinical data using computational approaches have the potential to detect early disease development and monitor drug treatments.
摘要：
关于血小板在血栓形成之外的作用已经获得了新的见解。血小板可以积聚在受损和发炎的组织中，作为检测和修复组织损伤的前哨。然而,通过释放几种可溶性因子，包括血栓烷A2（TXA2）和12-羟基二十碳四烯酸，和细胞外囊泡（EV），血小板可以激活血管细胞，基质,如成纤维细胞，免疫细胞，和癌细胞，导致动脉粥样硬化,血管再狭窄,组织纤维化，和肿瘤转移。血小板衍生的细胞外囊泡（PEV）在血小板被激活时释放，并可以将其货物转移到其他细胞类型，从而促进疾病的发展。PEV内化的抑制剂可以潜在地代表新的治疗工具。血小板和PEV都含有大量不同类型的分子，他们的组学评估以及使用计算方法与临床数据的整合有可能检测早期疾病发展和监测药物治疗。
